|Bid||221.79 x 1300|
|Ask||222.01 x 800|
|Day's Range||219.13 - 229.09|
|52 Week Range||210.94 - 321.70|
|Beta (3Y Monthly)||0.70|
|PE Ratio (TTM)||166.76|
|Earnings Date||May 7, 2019 - May 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||290.00|
SAN CLEMENTE, Calif., April 18, 2019 -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion.
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So before you...
ICU Medical Inc NASDAQ/NGS:ICUIView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for ICUI with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ICUI are favorable with net inflows of $72.41 billion. This was the highest net inflow seen over the last one-year.Error parsing the SmartText Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Baxter (BAX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
The healthcare business has suffered from product delays, stricter European regulations and two lost contracts in the United States. A plan to merge it with U.S.-based ICU Medical fell through in September because Smiths and ICU could not agree on terms. "Pursuing a demerger of Smiths Medical will lead to two stronger companies, each...maximising the opportunities in their respective markets," Chief Executive Andy Reynolds Smith said.
ICU Medical (ICUI) is well positioned to outperform the market, as it exhibits above-average growth in financials.
ICU Medical Inc is engaged in the development, manufacture and sale of medical devices used in infusion therapy, oncology and critical care applications. ICU Medical Inc had annual average EBITDA growth of 7.50% over the past ten years. GuruFocus rated ICU Medical Inc the business predictability rank of 2.5-star.
SAN CLEMENTE, Calif., March 01, 2019 -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion.
SAN CLEMENTE, Calif., Feb. 28, 2019 -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy.
Baxter International Inc said the U.S. Justice Department has closed an antitrust probe examining possible communication among producers of intravenous saline solutions during supply shortages that created higher prices. Baxter, which received a grand jury subpoena in 2017 as part of the investigation, said in a filing with the U.S. Securities and Exchange Commission on Thursday that the department informed it on Nov. 30 of its decision to end the probe. Other companies that in April 2017 disclosed receiving subpoenas as part of the investigation included Pfizer Inc and ICU Medical Inc, which earlier that year had acquired Pfizer's global infusion therapy business.
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Feb. 11, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
SAN CLEMENTE, Calif., Feb. 07, 2019 -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Building up an investment case requires looking Read More...
Today we are going to look at ICU Medical, Inc. (NASDAQ:ICUI) to see whether it might be an attractive investment prospect. Specifically, we're going to calculate its Return On Capital Read More...
SAN CLEMENTE, Calif., Dec. 27, 2018 -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion.
How far off is ICU Medical, Inc. (NASDAQ:ICUI) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is Read More...
Even though biotech markets are “down big this year,” Managing Director Mitchell Ng of Thessalus Capital says that there are “specific industries within the healthcare sector that are very promising,” such as gene editing companies. Yahoo Finance’s Alexis Christoforous speaks to him about the future for biotech in 2019.